Compare Aehr Test Systems (AEHR) vs McKesson Corporation (MCK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aehr Test Systems vs McKesson Corporation — how do they compare? Aehr Test Systems trades at $66.67 (market cap $2.11B), while McKesson Corporation trades at $817.97 (market cap $94.52B). The key difference: McKesson Corporation is far larger — about 44.8× Aehr Test Systems's market cap, and McKesson Corporation pays a 0.41% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.
| AEHR | MCK | |
|---|---|---|
Market Cap | $2.11B | $94.52B |
Sector | Technology | Health |
52-Week High | $116.58 | $995.69 |
52-Week Low | $13.29 | $659.01 |
Enterprise Value | $2.08B | $99.16B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR trades at $72.33, up 3.38% today, with a bullish technical signal driven by oversold RSI readings near 24.5, though moving averages remain bearish. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains negative profitability margins and cash flow. Recent news highlights strong order growth from AI and silicon photonics customers, including a follow-on system order announced June 17, 2026.
Outlook is mixed: robust order book and AI sector tailwinds support growth, but high P/S of 46.6 and persistent losses pose valuation risks. Analyst consensus is cautious with 33% buy ratings. Key risks include execution on orders and cash burn.
McKesson (MCK) trades at $807.33, up 2.67% with strong bullish momentum. The stock shows robust fundamentals with consistent earnings beats and revenue growth from $309B to $359B in 2025. Technical indicators signal bullish momentum with price above key support levels. Recent news highlights McKesson's growth in specialty pharma and oncology services, supported by positive analyst sentiment.
Outlook remains positive with 80% analyst buy ratings and $932.83 consensus price target, offering 15% upside. Risks include policy pressures and margin compression, but diversified portfolio and investment-grade rating provide stability. Earnings momentum and strategic investments position MCK for continued growth in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
